Author

Brian G. Feagan

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL
BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

Brian G. Feagan  et al.

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Gazing into the Crystal Ball: Current and Future Perspectives for Crohn’s Disease Complications (Boehringer Ingelheim)
Gazing into the Crystal Ball: Current and Future Perspectives for Crohn’s Disease Complications (Boehringer Ingelheim)

Brian G. Feagan  et al.

IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION

Brian G. Feagan  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Brian G. Feagan  et al.

FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY
FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY

Brian G. Feagan  et al.

PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY
PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan  et al.

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Brian G. Feagan  et al.

BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL
BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL

EFFICACY AND SAFETY OUTCOMES UP TO ~4 YEARS OF TREATMENT WITH FILGOTINIB 200 MG AMONG PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE SELECTIONLTE STUDY
EFFICACY AND SAFETY OUTCOMES UP TO ~4 YEARS OF TREATMENT WITH FILGOTINIB 200 MG AMONG PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE SELECTIONLTE STUDY

Brian G. Feagan  et al.

PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY
PREDICTORS OF RESPONSE TO FILGOTINIB IN ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE SELECTION STUDY

Brian G. Feagan  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY
ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Brian G. Feagan  et al.

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Brian G. Feagan  et al.

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

Brian G. Feagan  et al.

SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1? STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS
SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1? STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS

Brian G. Feagan  et al.

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION
LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

Brian G. Feagan  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Brian G. Feagan  et al.

GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Brian G. Feagan  et al.

Item 1 - 20 / 77
1
2 3 4